Annovis Bio Inc. to Present Alzheimer’s Advances at AAIC 2025: Key FAQs

What is Annovis Bio Inc. presenting at the AAIC 2025?

Annovis Bio Inc. will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap, including Phase III trial design, efficacy and safety data, and comparative pharmacokinetics of different drug formulations.

When and where is the AAIC 2025 taking place?

The Alzheimer’s Association International Conference (AAIC) will take place from July 27–31, 2025, in Toronto.

What is buntanetap?

Buntanetap is Annovis Bio Inc.’s lead candidate, a therapy targeting neurodegenerative diseases like Alzheimer’s and Parkinson’s by addressing multiple neurotoxic proteins to restore brain function.

How can I learn more about Annovis Bio Inc.’s presentation at AAIC 2025?

For more information, you can view the full press release at https://ibn.fm/w0fFP or visit the company’s website at www.AnnovisBio.com.

What is the goal of Annovis Bio Inc.’s therapies?

The goal of Annovis Bio Inc.’s therapies is to restore brain function and improve the quality of life for patients with neurodegenerative diseases by targeting multiple neurotoxic proteins.

Where is Annovis Bio Inc. headquartered?

Annovis Bio Inc. is headquartered in Malvern, Pennsylvania.

How can I stay updated on Annovis Bio Inc.’s latest news?

The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.

What is BioMedWire?

BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the Dynamic Brand Portfolio @ IBN.